Global Antispasmodics Drug Market - 2024-2031

Global Antispasmodics Drug Market - 2024-2031

The global antispasmodics drug market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Antispasmodics are a medicine that can help control some symptoms caused by the gut (intestines), specifically gut spasms. Antispasmodic medications treat symptoms like stomach pain and cramping (spasms). They are most commonly used to treat irritable bowel syndrome symptoms.

The main drugs involved in the antispasmodics drugs are dicyclomine hydrochloride, hyoscyamine, and loperamide hydrochloride. In addition, factors such as the high prevalence of irritable bowel syndrome and adoption of a sedentary lifestyle, high patient awareness level and improvement in treatment, and increasing investments and funding in the field of life science research drive this market.

Market Dynamics: Drivers

Growing Prevalence of Irritable Bowel Syndrome

The demand for the antispasmodics drug market is driven by multiple factors. Irritable bowel syndrome (IBS) is a long-term gastrointestinal disorder that can cause persistent discomfort. People can often manage their IBS symptoms with diet and lifestyle changes.

According to NCBI data published in October 2022, IBS is most frequent in South America at around 21% and least prevalent in Southeast Asia at 7%. In the United States, Canada, and Israel, IBS symptoms are 1.5 to 2 times more common in women than males.

In addition, the Public Health Agency of Canada predicted that about 260,000 Canadians have this disease in July 2021. Inflammatory bowel disease can occur at any age, however, it is most commonly diagnosed in older teenagers and young adults.

Moreover, major key players initiating the awareness programs would propel this market. For instance, in April 2024, Hyderabad-based Dr. Reddy’s Laboratories announced the roll-out of its condition management program DailyBloom IBS, India’s first integrated care plan for Irritable Bowel Syndrome (IBS).

The program is based on extensive research and is enabled by a mobile application developed in-house. DailyBloom IBS focuses on a comprehensive care plan that includes diet management, and psychological and physical wellness support for patients with IBS.

Restraints

Factors such as the side effects associated with the medication, stringent government guidelines lack of skilled professionals, adoption of sedentary lifestyles, and product recalls are expected to hamper the market.

Segment Analysis

The global antispasmodics drug market is segmented based on type, application, route of administration, end-user and region.

The irritable bowel syndrome segment accounted for approximately 54.5% of the antispasmodics drug market share

The irritable bowel syndrome segment is expected to hold the largest market share over the forecast period. Irritable bowel syndrome(IBS) is a collection of symptoms that affect your digestive system. It is a common but unpleasant gastrointestinal disorder. Irritable bowel syndrome patients experience excessive gas, abdominal pain, and cramping.

The highest rates of irritable bowel syndrome are assumed to be in developed countries, while the lowest are in developing regions; colder climate regions and urban areas have a higher rate of irritable bowel syndrome than warmer climate regions and rural areas.

Internationally, the incidence of irritable bowel syndrome ranges from 0.5-24.5 cases for ulcerative colitis to 0.1-16 cases per 100,000 person-years for Crohn's disease. Irritable bowel syndrome has a prevalence of 396 cases per 100,000 people in the United States each year. In the United States, in 2021, there will be approximately 3.5 million people suffering from inflammatory bowel disease. The prevalence of irritable bowel disease in the US population is expected to rise to around 4.5 million by 2030.

Antispasmodic drugs like Alverine citrate, in combination with simethicone, effectively reduced abdominal pain and discomfort; while otilonium bromide also improved defecation problems. An increasing number of populations facing irritable bowel syndrome is a major factor contributing to the significant growth of the segment in the forecast period.

In addition, key players in the industry introduce the innovative technological platforms that drive this market. For instance, in March 2021, Salix launched GastroHub for advanced practice providers, an educational website designed to provide nurse practitioners and physician assistants with relevant information for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy (HE).

Also, in August 2021, Mahana Therapeutics gears up to launch the IBS treatment app with $61M series B. The prescription-only, FDA-cleared Mahana IBS digital therapeutic guides users through a daily regimen of cognitive behavioral therapy to lessen the severity of their irritable bowel syndrome symptoms.

Geographical Analysis

North America accounted for approximately 41.5% of the antispasmodics drug market share

North America region is expected to hold the largest market share over the forecast period. Due to its well-established healthcare infrastructure and the growing number of organized healthcare systems.

Some of the factors propelling the market in these regions are the rising prevalence of gastrointestinal problems and increased government measures that look toward shorter periods of patent exclusivity for new medication applications. Furthermore, the industry is being driven by a huge population, rising disposable income, and increased patient awareness, to name a few aspects.

Moreover, in this region, key players introduce new products and approvals propel this market growth. For instance, in June 2023, Ironwood Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LINZESS (linaclotide) as a once-daily treatment for pediatric patients ages 6-17 years old with functional constipation.

LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population. Earlier this year, the FDA granted a 6-month priority review to our supplemental New Drug Application (sNDA), 4 months earlier than the standard review timeline. LINZESS is developed and marketed by AbbVie and Ironwood Pharmaceuticals in the United States.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the antispasmodics drug market. The pandemic has made it tougher to bring new medications to market in the hopes of earning market share or reaching sales projections. Aside from new diagnoses and regimen switching, marketing channels aren't as strong as before the epidemic. The few open channels continue to be dominated by COVID-19 programming.

COVID-19 has slowed down clinical trials across the board, notably those in the early stages of development. As traditional study sites closed, researchers were often unable to collect data remotely, and many patients became less willing to participate. Some therapeutic fields were particularly heavily damaged. While some development time can be made up, there are concerns about resource allocation and digital technology expenditures to keep trials running now and in the future.

Market Segmentation

By Type

● Dicyclomine hydrochloride

● Hyoscyamine

● Loperamide hydrochloride

By Application

● Irritable Bowel Syndrome

● Stomach Cramps

● Others

By Route of Administration

● Oral

● Injectable

● Sublingual

By End-Users

● Hospitals

● Online Pharmacy

● Retail Pharmacy

● Others

By Region

● North America
U.S.
Canada
Mexico

● Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe

● South America
Brazil
Argentina
Rest of South America

● Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific

● Middle East and Africa

Competitive Landscape

The major global players in the antispasmodics drug market include Sanofi, Teva Pharmaceuticals, Aurobindo Pharma, Sun Pharmaceuticals, Johnson & Johnson, Novartis, Pfizer, Lannett, Hikma Pharmaceuticals, and AbbVie Inc. among others.

Key Developments

⮚ On January 9, 2023, Lupin got USFDA approval for the generic antispasmodic drug. It received approval from the US drug regulator for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate extended-release tablets, 4 mg, and 8 mg. The drug is a generic equivalent of Toviaz extended-release tablets, 4 mg and 8 mg, of Pfizer Inc. This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). This medication belongs to the class of drugs known as antispasmodics.

⮚ On October 17, 2022, Silo Wellness Inc. Oregon's only publicly traded psychedelics company, is pleased to announce it has closed its acquisition of 100% of Dyscovry Science Ltd. a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome.

⮚ On April 4, 2022, Ardelyx announced the US launch of IBSRELA a new first-in-class treatment for IBS-C in Adults. The launch of IBSRELA, a first-in-class NHE3 inhibitor, provides a new treatment option with a novel mechanism of action and impressive efficacy data to address the constipation and multiple abdominal symptoms commonly seen in patients with IBS-C, as demonstrated in the Phase 3 clinical trials.

Why Purchase the Report??

● To visualize the antispasmodics drug market segmentation based on type, application, route of administration, end-user, and region as well as understand key commercial assets and players.

● Identify commercial opportunities by analyzing trends and co-development.

● Excel data sheet with numerous data points of antispasmodics drug market level with all segments.

● PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

● Product mapping is available in Excel consisting of key products of all the major players.

The antispasmodics drug market report would provide approximately 70 tables, 63 figures, and 181 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies